Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

Drugs

Volumn 54, Issue 3, 1997, Pages 355-368

  Scheen, André J ^a,b  

^a CHU SART TILMAN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANOREXIGENIC AGENT; BENFLUOREX; BIGUANIDE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN; MIGLITOL; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; VANADIUM DERIVATIVE;

GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYPERLIPIDEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW;

EID: 0030826933     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754030-00001     Document Type: Review

References (144)

1. Scheen AJ, Lefèbvre PJ. Pathophysiology of type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology: oral antidiabetics. Berlin: Springer Verlag, 1995: 7-42
2. Lefèbvre PJ, Scheen AJ. Management of non-insulin-dependent diabetes mellitus. Drugs 1992; 44 Suppl. 3: 29-38
3. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet 1995; 343: 95-100
4. Lefèbvre PJ, Scheen AJ. Improving the action of insulin. Clin Invest Med 1995; 18: 340-7
5. Alberli KGMM, Gries FA, Jervell J, et al. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabetic Med 1994; 15: 899-909
6. American Diabetes Association. Consensus statement: the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-8
7. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-45
8. Kuhlmann J, Puls W, editors. Oral antidiabetics. In: Handbook of experimental pharmacology. Berlin: Springer Verlag, 1995
9. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study Group (UKPDS) 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ 1995; 310: 83-8
10. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes, a progressive disease. Diabetes 1995; 44: 1249-58
11. Melander A, Bitzen P-O, Faber O, et al. Sulphonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37: 58-72
12. Groop LC. Sulfonylureas and NIDDM. Diabetes Care 1992; 15: 737-54
13. Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. Chichester: J Wiley, 1992: 745-72
14. Beck-Nielsen H, Hother-Nielsen O, Pedersen P. Mechanism of action of sulfonylureas with special reference to the extra-pancreatic effect: an overview. Diabetic Med 1988; 5: 613-20
15. Pontiroli AE, Calderara A, Pozza G. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev 1994; 10: 31-43
16. Berelowitz M, Fischette C, Cefalu W, et al. Comparative efficacy of a once-daily controlled-released formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 1994; 17: 1460-4
17. Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997; 20: 597-606
18. Peters AL, Davidson MB. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab 1996; 81: 2423-7
19. Melander A. Oral antidiabetic drugs: an overview. Diabetic Med 1996; 13 Suppl. 6: S143-7
20. Campbell IW. Hypoglycemia and type II diabetes: sulfonylureas. In: Frier B, Fisher M, editors. Hypoglycemia and diabetes: clinical and physiological aspects. London: Edward Arnold, 1993: 387-92
21. Stahl M, Berger W. Sulfonylurées: pharmacologie et risque hypoglycémique. In: Journées de Diabétologie de l'Hôtel-Dieu. Paris: Flammarion Médecine-Sciences, 1995: 108-19
22. Scheen AJ, Lefèbvre PJ. Antihyperglycaemic agents: drug interactions of clinical importance. Drug Safety 1995; 12: 32-45
23. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives: implications for the treatment of NIDDM? Diabetologia 1995; 38: 116-21
24. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996; 39: 503-14
25. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
26. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. Chichester: J Wiley, 1992: 773-95
27. Scheen AJ, Lefèbvre PJ. La metformine: des effets métaboliques aux indications thérapeutiques. Med Hyg 1993; 51: 1993-8
28. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49
29. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9
30. Andreani D, Lefèbvre P, editors. Metformin: mechanisms of action and clinical use. Diabetes Metab Rev 1995; 11 Suppl. 1: S1-108
31. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-9
32. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Research 1994; 30: 187-228
33. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-71
34. Gregorio F, Ambrosi F, Filipponi P, et al. Is metformin safe enough for ageing type 2 diabetic patients? Diabete Metab 1996; 22: 43-50
35. Lebovitz HE. Oral antidiabetic drugs: the emergence of alpha glucosidase inhibitors. Drugs 1992; 44 Suppl 3.: 21-8
36. Lefèbvre PJ, Standl E, editors. New aspects in diabetes: treatment strategies with alpha-glucosidase inhibitors. Berlin-New York: de Gruyter, 1992
37. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-54
38. Nieuwenhuijzen Kruseman AC, Sels JPJE, Wolffenbuttel BHR, editors. α-Glucosidase inhibitors in diabetes. Eur J Clin Invest 1994; 24 Suppl. 3: 1-54
39. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-35
40. Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994; 154: 2442-8
41. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-51
42. Holman RR, Cull CA, Turner RC. Glycaemic improvement over one year in a double-blind trial of acarbose in 1,946 NIDDM patients [abstract]. Diabetologia 1996; 39 Suppl 1.: A44
43. Turner RC, Holman RR. Insulin use in NIDDM: rationale based on pathophysiology of disease. Diabetes Care 1990; 13: 1011-20
44. Genuth S. Insulin use in NIDDM. Diabetes Care 1990; 13: 1240-64
45. Genuth S. Management of the adult onset diabetic with sulfonylurea drug failure. Endocrinol Metab Clin North Am 1992; 21: 351-70
46. Scheen AJ. Insulin therapy in the treatment of NIDDM. IDF Bull 1996; 41: 16-8
47. Colwell JA. DCCT findings applicability and implications for NIDDM. Diabetes Rev 1994; 2: 277-91
48. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in Type II diabetes. Diabetes Rev 1995; 3: 308-34
49. Colwell JA. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 131-5
50. Colwell JA. Should we use intensive insulin therapy after oral agent failure in type II diabetes? Diabetes Care 1996; 19: 896-8
51. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17
52. Stout RW. Insulin and atheroma: 20-year perspective. Diabetes Care 1990; 13: 631-51
53. Malmberg K, DIGAMI Study Group. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65
54. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 1994; 17: 1542-4
55. Hermann LS. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 1990; 13 Suppl 3.: 37-41
56. Scheen AJ, Castillo MJ, Lefèbvre PJ. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. Acta Clin Belg 1993; 48: 259-68
57. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-64
58. Scheen AJ, Lefèbvre PJ. Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract 1989; 6: S33-43
59. Castillo M, Scheen AJ, Paolisso G, et al. The addition of glipizide to insulin therapy in type II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol 1987; 116: 364-72
60. Yki-Järvinen H, Kauppila M, Kujansuue E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-33
61. Golay A, Guillet-Dauphiné N, Fendel A, et al. The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 1995; 11 Suppl. 1: S63-7
62. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvements in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107-12
63. Hotta N, Kakuta H, Koh N, et al. The effects of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy. Diabetic Med 1993; 10: 355-8
64. Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-32
65. Van der Wal PS, Scheen A, Van Gaal L, et al. Efficacy of bedtime NPH insulin alone us compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure to oral hypoglycemic agents [abstract]. Diabetes 1996; 45 Suppl. 2: 286A
66. Pi-Sunyer FX. Weight and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1996; 63 Suppl.: 426S-9S
67. Scheen AJ, Lefèbvre PJ. Pharmacological treatment of the obese diabetic patient. Diabete Metab 1993; 19: 547-59
68. Arnaud O, Nathan C. Antiobesity and lipid-lowering agents with antidiabetic activity. In: Bailey CJ, Flatt PR, editors. New antidiabetic drugs. Nishimura: Smith-Gordon, 1990: 133-42
69. Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diabetes Rev 1997; 5: 83-103
70. Davis R, Faulds D. Dexfenfluramine: an updated review of its therapeutic use in the management of obesity. Drugs 1996; 52: 696-724
71. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. Obesity Res 1995; 3 Suppl. 4: 491S-6S
72. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabetic Med 1994; 11: 105-10
73. Scheen AJ, Paolisso G, Salvatore T, et al. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 1991; 14: 325-32
74. Maheux P, Ducros F, Bourque J, et al. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obesity 1997; 21: 97-102
75. Scheen AJ. Antiobesity drugs in the management of diabetes. Int Diabetes Monit 1997; 9(1): 1-8
76. Kosmiski L, Eckel RH. Anorectic agents in non-insulin dependent diabetes mellitus. Curr Opin Endocrinol Diabetes 1997; 4: 36-9
77. Reaven GM, editor. Insulin resistance, hyperinsulinemia and diabetes: contribution of benfluorex. Diabetes Metab Rev 1993; 9 Suppl. 1: S1-S72
78. Giustina A, Rocca I, Romanelli G, et al. Effects of benfluorex on glucose tolerance, metabolic control, beta-cell secretion, and peripheral sensitivity to insulin in obese type II diabetic patients on a body weight-maintaining diet. Curr Ther Res 1989; 45: 33-42
79. Cavallo-Perin P, Estivi P, Boine L, et al. Benfluorex and blood glucose control in non-insulin-dependent diabetic patients. J Endocrinol Invest 1991; 14: 109-13
80. Bianchi R, Bongers V, Bravenboer B, et al. Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. Diabetes Care 1993; 16: 557-9
81. Pontiroli AE, Pacchioni M, Piatti PM, et al. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. J Clin Endocrinol Metab 1996; 81: 3727-32
82. Bailey CJ, Flatt PR, editors. New antidiabetic drugs. Nishimura: Smith-Gordon, 1990
83. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992; 15: 792-805
84. Rachman J, Turner RC. Drugs on the horizon for treatment of type 2 diabetes. Diabetic Med 1995; 12: 467-78
85. Wolffenbuttel BHR, Graal MB. New treatments for patients with type 2 diabetes mellitus. Postgrad Med J 1996; 72: 657-62
86. Turner RC, editor. New oral antidiabetic agents: from today to tomorrow. Diab Res Clin Pract 1995; 28 Suppl.: S1-208
87. Bischoff H, Lebovitz HE. Oral antidiabetic drugs in research and development. In: Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology: oral antidiabetics. Berlin: Springer Verlag, 1995: 651-96
88. Matthews DR, Riddle MC, editors. Proceedings of the International Glimepiride Symposium. Hormone Metab Res 1995; 28: 403-526
89. Goldberg RB, Holvey SM, Schneider J, et al. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996; 19: 849-56
90. Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996; 19: 1194-9
91. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res 1995; 27: 263-6
92. Wolffenbuttel BHR, Nijsl L, Sels JPJE, et al. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113-6
93. Kikuchi M. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabetic Med 1996; 13 Suppl. 6: S151-5
94. Skillman CA, Raskin P. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67 582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients. Diabetes Care 1997; 20: 591-6
95. Robertson RP, Halter JB, Porte D. A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 1976; 57: 791-5
96. Broadstone VL, Pfeifer MA, Bajaj V, et al. α-Adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes 1987; 36: 932-7
97. ATP channels and interaction with the exocytotic machinery. Diabetes 1996; 45: 1610-8
98. Holst JJ, Nauck MA, Deacon CF, et al. Potential of GLP-1 in diabetes management. In: Lefèbvre PJ, editor. Handbook of experimental pharmacology: glucagon III. Vol. 123. Berlin: Springer Verlag, 1996: 311-26
99. Holst JJ. GLP-1 in NIDDM. Diabetic Med 1996; 13 Suppl. 6: S156-60
100. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-22
101. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-4
102. Gutniak MK, Linde B, Holst JJ, et al. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in non-insulin dependent diabetes. Diabetes Care 1994; 17: 1039-44
103. Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose responses, and insulin secretion after liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36)amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-32
104. Juntti-Berggren L, Pigon J, Karpe F, et al. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996; 19: 1200-6
105. Gutniak MK, Larsson H, Heiber SJ, et al. Potential therapeutic levels of glucagon-like peptide 1 achieved in humans by a buccal tablet. Diabetes Care 1996; 19: 843-8
106. Gutniak M, Larsson H, Sanders S, et al. GLP-1 tablet, a new therapeutic alternative for NIDDM [abstract]. Diabetologia 1996; 39 Suppl. 1: A43
107. Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075-8
108. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9
109. Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated re- ceptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-8
110. Chaiken RL, Eckert-Norton M, Pasmantier R, et al. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia 1995; 38: 1307-12
111. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-93
112. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203
113. Mimura K, Umeda F, Hiramatsu S, et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med 1994; 11: 685-91
114. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-9
115. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone, a new hypoglycemic agent, in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151-6
116. Reaven GM. The fourth musketeer: from Alexandre Dumas to Claude Bernard. Diabetologia 1995, 38: 3-13
117. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 45: 3-10
118. Fulcher GR, Alberti KGMM. Hypoglycaemic action of anti-lipolytic agents. In: Bailey CJ, Flatt PR, editors. New antidiabetic drugs. Nishimura: Smith-Gordon, 1990: 143-55
119. Fulcher GR, Walker M, Catalano C, et al. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes 1992; 41: 1400-8
120. Vaag AA, Beck-Nielsen H. Effects of prolonged acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol 1992; 127: 344-50
121. Dean JD, McCarthy S, Betteridge DJ, et al. The effect of acipimox on non-insulin-dependent diabetic patients with persistent hyperlipidaemia. Diabetic Med 1993; 9: 611-5
122. Saloranta C, Taskinen M-R, Widen E, et al. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 1993; 42: 1559-66
123. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 1992; 15: 773-84
124. Wolf HPO. Possible new therapeutic approach in diabetes mellitus by inhibition of carnitine palmitoyltransferase 1 (CPTI). Horm Metabol Res 1992; Suppl. 26: 62-7
125. Ratheiser K, Schneeweiss B, Waldhäusl W, et al. Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic-glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Metabolism 1991; 40: 1185-90
126. Hübinger A, Weikert G, Wolf HPO, et al. The effect of etomoxir on insulin sensitivity in type 2 diabetic patients. Horm Metabol Res 1992; 24: 115-8
127. Lefèbvre P, Paolisso G, Scheen A. The role of glucagon in non-insulin-dependent (type 2) diabetes mellitus. In: Sakamoto N, Angel A, Hotta H, editors. New directions in research and clinical works for obesity and diabetes mellitus. Excerpta Medica, 1991: 25-9
128. Lefèbvre PJ. Glucagon and diabetes. In: Lefèbvre PJ, editor. Handbook of experimental pharmacology: glucagon III. Vol. 123. Berlin: Springer Verlag, 1996: 115-31
129. Amatruda JM, Livingston JN. The search for glucagon antagonists. In: Lefèbvre PJ, editor. Handbook of experimental pharmacology: glucagon III. Vol. 123. Berlin: Springer Verlag, 1996: 133-47
130. Shechter Y. Insulin-mimetic effects of vanadate: possible implications for future treatment of diabetes. Diabetes 1990; 39: 1-5
131. Goldfine AB, Simonson DC, Folli F, et al. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab 1995; 80: 3311-20
132. Cohen N, Halberstam M, Shlimovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995; 95: 2501-9
133. Halberstam M, Cohen N, Shlimovich P, et al. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996; 45: 659-66
134. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996; 45: 1130-5
135. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-8
136. Hotamisligil GS, Peraldi P, Spiegelman BM. The molecular link between obesity and diabetes. Curr Opin Endocrinol Diab 1996; 3: 16-23
137. Ofei F, Hurel S, Newkirk J, et al. Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-5
138. Scheen AJ, Castillo MJ, Paquot N, et al. No effect of neutralization of TNF-α on insulin-mediated glucose disposal in obese insulin-resistant subjects [abstract]. Diabetologia 1996; 39 Suppl. 1: A153
139. Workshop Proceedings. Gastrointestinal control of glycaemia. Diabetic Med 1996; 13 Suppl. 5: S1-S48
140. Johnson AB, Taylor R. Does suppression of postprandial blood glucose excursions by the α-glucosidase inhibitor miglitol improve insulin sensitivity in treated type II diabetic patients? Diabetes Care 1996; 19: 559-63
141. Kingma PJ, Menheere PPCA, Sels JP, et al. Alpha-glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 1992; 15: 478-83
142. Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994; 17: 20-9
143. Castillo MJ, Scheen AJ, Lefèbvre PJ. Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology. Diabete Metab 1995; 21: 3-25
144. Kolterman OG, Schwartz S, Coder C, et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996; 39: 492-9